Company intelligence / Profile preview
Y-mAbs Therapeutics, Inc.
New York, New York, United Statesymabs.com ↗
- Ownership
- Public · YMAB
- Development stage
- Other
01
Overview
Y-mAbs has FDA-approved treatment DANYELZA (naxitamab-gqgk) for patients with relapsed or refractory high-risk neuroblastoma. The company is conducting Phase I/II and Phase II clinical trials for various indications.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodies (BsAbs)VaccinesRadioimmunotherapiesDiagnostics
- Industry
- Biotech
02
Drug pipeline
23 assets22 more assets in the full pipeline.
03
Partnerships
Memorial Sloan Kettering Cancer Center (MSKCC)
Beyond the preview
Go deeper on Y-mAbs Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Y-mAbs Therapeutics, Inc..